Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01356628 · ClinicalTrials.gov registry record · Phase 2
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
A Phase 2 study of Liver Cancer and Advanced Hepatocellular Carcinoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT01356628 is a Phase 2 study of Liver Cancer and Advanced Hepatocellular Carcinoma that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 23 participants, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01356628, a Phase 2 study of Liver Cancer and Advanced Hepatocellular Carcinoma, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2 Study of PD-0332991 in the treatment of patients with Advanced Hepatocellular Carcinoma (HCC), a type of adenocarcinoma and the most common type of liver tumor. PD-0332991 is a compound that stops the tumor cell from entering the Synthesis phase of the cell cycle, therefore stopping DNA multiplication and decreased tumor cell copying.
Conditions Studied
Interventions
- DRUG PD-0332991
Study Locations (1)
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2011-05-25 |
| Est. Completion | 2023-12-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01356628
The ClinicalTrials.gov registry entry for NCT01356628 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which PD-0332991 is the first listed.
NCT01356628 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01356628 about?
NCT01356628 is a clinical study titled "A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer". This is a Phase 2 Study of PD-0332991 in the treatment of patients with Advanced Hepatocellular Carcinoma (HCC), a type of adenocarcinoma and the most common type of liver tumor. PD-0332991 is a compound that stops the tumor cell from entering the Synthesis phase of the cell cycle, therefore stoppin...
What is the current status of trial NCT01356628?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2011-05-25. Estimated completion is 2023-12-16.
What conditions does trial NCT01356628 study?
This clinical trial studies the following conditions: Liver Cancer, Advanced Hepatocellular Carcinoma, HCC.
What interventions are being tested in trial NCT01356628?
The interventions under investigation include: PD-0332991 (DRUG).
Who is sponsoring clinical trial NCT01356628?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01356628 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
RECRUITING · Phase 2
-
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
-
Y-90 Treatment Response Using Transarterial Radioembolization
RECRUITING · Phase 2
-
Domvanalimab and Zimberelimab in Advanced Liver Cancers
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.